Biomind Labs Inc. Stock Analysis BMND.NE

Biomind Labs, Inc. is a biotech research and development company focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is headquartered in Canelones, Ontario and currently employs 2 full-time employees. The company went IPO on 2021-07-27. The firm is focused on transforming biomedical sciences knowledge into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, the Company is developing novel pharmaceutical formulations of the main psychedelic molecules, N, N-dimethyltryptamine (DMT), 5- MeO-DMT, and mescaline (collectively, the Molecules), for treating a wide range of therapeutic indications. DMT is a serotonergic psychedelic that exerts its effects through serotonergic receptors in the brain, including 5-HT2A, 5-HT1A, 5-HT2C and 5-HT7 receptors, among others. Under the 5-MeO-DMT Program, it is focused on two drug candidates: the BMND05: 5-MeO-DMT novel formulation indicated for Chronic Pain and the BMND08: 5-MeO-DMT novel formulation indicated for Alzheimer’s disease. Mescaline is a psychedelic alkaloid of the phenethylamine class.